Provectus Biopharmaceuticals, Inc. (PVCT)
OTC PINK OTC PINK Primary 
XSTU Summary
PVCT Chart
Provectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call Transcript
Provectus Biopharmaceuticals, Inc. (OTC:PVCT) Q4 2024 Results Conference Call November 14, 2024 2:00 PM ET Company Participants Alyssa Barry - Co-Founder & Principal of Investor Relations, Alliance Advisors IR Ed Pershing - Chairman Dominic Rodrigues - Board Vice Chairman Alyssa Barry Good afternoon, good morning, good evening, depending on where you are. Welcome to Provectus Biopharmaceuticals Fourth Quarter Investor Update.
Provectus Biopharmaceuticals, Inc. (PVCT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Provectus Biopharmaceuticals, Inc. ever had a stock split?
Provectus Biopharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Dominic Rodrigues C.F.A. CEO | OTC PINK Exchange | 74373P108 CUSIP |
| US Country | 6 Employees | - Last Dividend | 11 Apr 2002 Last Split | - IPO Date |
Overview
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering the development of novel immunotherapy medications. These advancements are substantially based on halogenated xanthenes, signifying a significant focus on innovative cancer treatment methodologies. Initially known as Provectus Pharmaceuticals, Inc., the company transitioned its name to Provectus Biopharmaceuticals, Inc. in December 2013. Since its incorporation in 2002, it has situated its headquarters in Knoxville, Tennessee, underscoring its commitment to advancing healthcare through groundbreaking research and development activities in the field of biopharmaceuticals.
Products and Services
The company's robust pipeline is primarily focused on the development and refinement of immunotherapeutic agents aimed at treating a wide spectrum of cancer types, alongside other diseases. Notable products and services include:
- PV-10: This investigational autolytic cancer immunotherapy represents the forefront of Provectus Biopharmaceuticals' portfolio. Intended for adult solid tumor cancers, PV-10 is currently under study for effectiveness against melanoma, gastrointestinal tumors (including hepatocellular carcinoma and colorectal cancer metastatic to the liver), neuroendocrine tumors metastatic to the liver, uveal melanoma metastatic to the liver, and a range of pediatric solid tumor cancers (such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma).
- Oral Formulations of cGMP RBS: In its pursuit of more versatile treatment options, Provectus is developing oral formulations of current good manufacturing practice rose bengal sodium (cGMP RBS). These are aimed at adult solid tumor cancers (head and neck, breast, testicular, colorectal) and pediatric blood cancers (including leukemia), demonstrating a wide-reaching potential. The investigational formulations are also being considered for the treatment of coronavirus acute respiratory syndrome, multi-drug resistant gram-negative bacteria, and various eye diseases, such as infectious keratitis.
- PH-10: Beyond its cancer-focused initiatives, Provectus Biopharmaceuticals is delving into treatments for skin conditions. PH-10, an investigational immuno-dermatology agent, is being studied for its efficacy in treating inflammatory dermatoses, including psoriasis and atopic dermatitis. This highlights the company's dedication to addressing a broad spectrum of health issues through innovation in immunotherapy.
Contact Information
